The company is focused on commercializing an FDA-approved prescription medication, TRB-N0224, which is designed to prevent and control canine periodontal disease. In addition to this lead candidate, Traverse Biosciences is also exploring other therapeutic indications for TRB-N0224 and has a pipeline of additional drug candidates with potential applications in both human and veterinary medicine. The company's business model is centered around achieving key technical milestones, identifying validated market opportunities, and implementing a clear exit strategy. With the support of investors and stakeholders, Traverse Biosciences aims to mitigate product development risks and add tangible commercial value to its assets.